Managing infection with Magnesium microparticles

Intensive livestock systems are inherently prone to disease due to high stocking densities and environmental stressors, making infection management a critical component of animal welfare. Historically, antibiotics have been the cornerstone of disease prevention and treatment in these systems. However, the global rise of AMR has rendered this approach unsustainable, threatening both animal and human health.

Reducing antibiotic use without sacrificing productivity or welfare poses a complex challenge. Producers urgently need effective, scalable alternatives that not only control infections but also prevent the emergence of resistant pathogens, ensuring the long-term viability of intensive farming practices.

This innovative research project shepherded by SAAFE, Calix and UniSA explores the potential of magnesium oxide microparticles and its derivatives as antimicrobial alternatives.

The project will evaluate the safety and efficacy of these materials in managing infections, applicable across various livestock systems—pigs, poultry, dairy, and aquaculture. With a focus on in vitro and in vivo studies, the research aims to develop formulations that improve animal health and productivity while minimizing antibiotic reliance.

• Develop and characterize antimicrobial materials and formulations
• Establish protocols for evaluating their efficacy and safety for use in livestock management
• Demonstrate the effectiveness of these alternatives in reducing pathogenic bacteria and biofilms, with minimal risk of resistance development

Ultimately, the project will provide scientifically validated solutions that reduce antibiotic dependency, maintain animal welfare, and position Australian producers as global leaders in AMR mitigation.

Agriculture industry, consumers

3 years

Calix is an environmental technology company solving global challenges.

University of South Australia

Currently in its second year, the project has screened more than 50 different formulations for antimicrobial efficacy and safety in vitro, with lead candidates now undergoing assessment for their ability to prevent or treat established biofilm infections.

The lead candidates are now undergoing assessment for their ability to prevent or treat established biofilm infections, in both in vitro and in vivo models.